Le Lézard
Classified in: Ebola virus, Health, Science and technology

2017 Gene Replikin Counts in Global MERS-CoV Increase Four-Fold Over 2008 Count



BOSTON, Dec. 7, 2017 /PRNewswire/ -- Replikins Ltd. this week reported to the Healthcare Emergency Management Program of Boston University School of Medicine a four-fold increase in gene Replikin Counts in Global MERS-CoV from 2008 to 2017 (p<0.001) ? the highest ever recorded on Pubmed for MERS-CoV (See Figure below).

The dramatic increase in gene Replikin Count (number of Replikins per 100 amino acids) serves as a predictor of severe outbreaks of a "new" mutated MERS-CoV, and should be compared with the same phenomenon reported for influenza H1N1 in 2008 predicting the 2009 pandemic, of H3N2 for several years 2004-2017, for Zika virus in 2015 and February 2017, and for Influenza H5N8 in November 2017.  

The increases also are accompanied by a marked increase in mutation rate. The resultant substitution of the MERS-CoV antigenic base increases the risk that vaccines and blockers based on virus structures before 2017 will be less effective against the MERS-CoV antigenic base currently in circulation.

With over three million Replikins automated analyses of 18 virus genes, one to four years advance notice of the outbreaks consistently provide time for both public health preparations and the synthesis and testing of blockers and vaccines, overcoming the organism's advantage of surprise. 

The prediction one year in advance of the H1N1 2009 Pandemic, and 6 months in advance of the sudden unexpected cessation of the 2014 Ebola outbreak, as well as the other consistent advance information of outbreaks and cessations over 10 years, has led to the formation of the Replikins SurveillanceServicetm.  The Gates Foundation and the World Bank have recently urged more efforts and new efforts in advance of the outbreak.

Because, to our knowledge, it is the only source of reliable automated quantitative advance information on infectious disease outbreak and cessation, the Replikins SurveillanceServicetm uniquely can offer the solid phase synthesis in seven days of up-to-date Replikin blockers and vaccines against the markedly mutated MERS-CoV currently in circulation, and against mutations in other viruses and bacteria.

The Service also offers the particular expertise of those Service subscribers including the Boston University School of Medicine Healthcare Emergency Management Program, which, in addition to the basic subscription to receive advance information, wish to work with other Service subscribers and Replikins,Ltd. in the effort to ameliorate and eventually prevent infectious disease outbreaks and pandemics.

For further information and subscription to
Replikins SurveillanceServicetm, contact:

Samuel Bogoch, MD,PhD.
187303@email4pr.com 
tel.646-320-5910

copyright Replikins,Ltd. 2017

SOURCE Replikins Ltd.


These press releases may also interest you

at 03:00
SAN RAFAEL, Calif., Feb. 24, 2018 /PRNewswire-PRWeb/ -- Michael Moskowitz, MD, MPH and Randy Perretta of Anandamedicine, Bill Heriot of Liposome Formulations Inc, George Bianchini of Medi-Cone and Leonard Leinow of Synergy Wellness have joined to...

at 03:00
FORT LAUDERDALE, Fla., Feb. 24, 2018 /PRNewswire-PRWeb/ -- The fourth annual Aestheticians' Choice Awards (ACA) results are in and EndoSystems technology, the endermologie® Cellu M6® Integral 2, won first place for favorite sculpting machine. Each...

23 fév 2018
The registered nurses of Baystate Franklin Medical Center, represented by the Massachusetts Nurses Association, agreed on Friday to withdraw their one-day strike notice after Baystate Health requested the withdrawal in order to return to the...

23 fév 2018
Attendees at the 2018 START National Training Institute (SNTI), held May 7 ? 9 in Boston, Mass., will notice Therap among the list of sponsors at this year's event.  Providers supporting individuals with intellectual and developmental disabilities...

23 fév 2018
Oncolytics Biotech® Inc. , a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn "cold" tumors "hot", today announced that it...

23 fév 2018
Apollo Medical Holdings, Inc. ("ApolloMed" or the "Company") , an integrated population health management company, today announced that, as previously reported on a Current Report on Form 8-K to the Securities and Exchange Commission, the Company's...




News published on 7 december 2017 at 10:39 and distributed by: